Gill Davey, incontinence nurse and spokesperson for Bladder Health UK, says: “Over the last 20 years, there has been a gradual shift in attitude around incontinence, and that’s mainly down to improved public awareness, thanks to TV advertising and celebrities speaking out.
"Incontinence is not a normal part of ageing. However, older people tend to exercise less, don’t drink enough and are on lots of medication, which are all risk factors. Pharmacies are key in helping to direct customers and giving good advice.”
At Essity (owner of the Tena brand), marketing director Ruth Gresty says: “Incontinence remains a taboo subject for many. Tena understands that supporting individuals with incontinence starts with destigmatising the condition. We aim to do that with direct communications and a wide assortment of products, to help individuals feel more comfortable.”
Numark medication safety officer and information pharmacist Jacquie Lee says: “Due to the prevalence of advertising for absorbent products, customers may assume that managing leakage is the only option. They may not realise that treatments, lifestyle modifications and behavioural techniques can significantly improve or even resolve the symptoms of overactive bladder and incontinence. By promoting awareness of available treatments, managing expectations and reducing the associated stigma, customers can be empowered to seek appropriate care and improve their quality of life, regardless of age.”
In May, the MHRA announced its decision to maintain POM status for the overactive bladder (OAB) medication Aquiette on safety grounds. The manufacturer of the oxybutynin-containing treatment, Maxwellia, expressed its disappointment with the decision. CEO Anna Maxwell said: “We’re incredibly disappointed with the MHRA’s decision not to improve access to a life-changing, low-dose, short-term overactive bladder medicine.
“Doctors who supported the reclassification believe that the MHRA has turned down an effective and easy way for women to treat their early stage OAB without the need for a prescription.” Maxwell added that although the reclassification opportunity has passed for now, the company would strive to innovate for OAB sufferers.
The Royal Pharmaceutical Society (RPS) was pleased with the MHRA’s decision, however. Laura Wilson, RPS director for Scotland, said: “Oxybutynin is a well established product with a known side effect profile. However, there is mounting evidence implicating the active ingredient with brain health harm, cognitive decline, the progression of dementia and greater mortality in those taking it. The extensive side effect profile of oxybutynin means that without access to patients notes, it could be challenging to determine its suitability in patients who do not fully disclose all current and previous medical diagnosis.
“Pharmacy teams do a great deal to manage safety, identify red flags prior to supply and ensure safe and appropriate use of P medicines. However, RPS does not believe that the balance of benefit and harm make this a suitable product for P medicine status.”
Numark’s lead information pharmacist Kenny Chan says: “Pharmacists are already stretched with their resources and time. Changing an item that has safety concerns to be available without prescription would require more time during the consultation process and may surface further questions from patients which pharmacists may not be able to answer.”